The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The North America travel vaccines market size reached US$ 1.7 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 2.5 Billion by 2027, exhibiting a growth rate (CAGR) of 6.89% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Vaccines are defined as biological preparations that protect the human body against severe and potentially deadly diseases. They generally consist of an agent made from the surface protein, toxins, weakened or killed forms of the disease-causing microorganisms. Vaccination enables the body to produce antibodies, which provide a shield in case the person is exposed to the disease. For travel vaccines, also known as travel immunizations, travelers are vaccinated 4 to 6 weeks before the journey. These can be differentiated between recommended and required vaccines. Wherein, required vaccines are essential for the individual to get before entering a country. However, recommended vaccines are those which the traveler may need because of a potential infection threat in the country or a part of that country. Some of the most common vaccine-preventable, travel-related diseases include influenza, meningitis, rabies, tick-borne encephalitis, polio, diphtheria, tetanus, pertussis, etc.
Note: Values and trends in the above chart consists of dummy data and are only shown here for representation purpose. Kindly contact us for the actual market size and trends.
To get more information about this market, Request Sample
North America travel vaccines market is currently being driven by several factors. One of the key factors driving the demand of travel vaccines is their ability to prevent the risk of disease epidemic. Moreover, vaccination provides immunity to individuals, travelling to places where there is a high risk of exposure or contracting a specific disease. As a result, governments in the region have mandated vaccination before visiting certain destinations with a high prevalence of infectious diseases. Other factors driving the demand of travel vaccines in the region include rising number of travelers, government initiatives, technological advancements such as combination vaccines and needle free techniques, etc.
IMARC Group provides an analysis of the key trends in each sub-segment of the North America travel vaccines market report, along with forecasts at the regional and country level from 2022-2027. Our report has categorized the market based on composition and disease.
|Base Year of the Analysis||2021|
|Segment Coverage||Composition, Disease, Country|
|Countries Covered||United States, Canada, Mexico|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2699
Five User License: US$ 3699
Corporate License: US$ 4699
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
The North America travel vaccines market was valued at US$ 1.7 Billion in 2021.
We expect the North America travel vaccines market to exhibit a CAGR of 6.89% during 2022-2027.
The high prevalence of travel-related diseases, such as influenza, meningitis, tick-borne encephalitis,
etc., is primarily driving the North America travel vaccines market.
The sudden outbreak of the COVID-19 pandemic has led to the rising adoption of novel coronavirus
vaccine as a mandate travel requirement for international travelers in North America to avoid the risk of
Based on the composition, the North America travel vaccines market has been segmented into mono vaccines and combination vaccines. Currently, combination vaccines hold the majority of the total
Based on the disease, the North America travel vaccines market can be divided into hepatitis A, DPT,
yellow fever, typhoid, hepatitis B, measles and mumps, rabies, meningococcal, varicella, Japanese encephalitis, and others. Among these, hepatitis A currently represents the largest market share.
On a regional level, the market has been classified into United States, Canada, and Mexico, where the
United States currently dominates the North American market.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at